Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática
Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults...
Guardado en:
Autores principales: | , , , , , |
---|---|
Lenguaje: | Spanish / Castilian |
Publicado: |
Sociedad Médica de Santiago
2015
|
Materias: | |
Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:scielo:S0034-98872015000100002 |
---|---|
record_format |
dspace |
spelling |
oai:scielo:S0034-988720150001000022015-08-11Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemáticaMarzi,MartaWeitz,DaríoAvila,AylénMolina,GabrielCaraballo,LucíaPiskulic,Laura Arrhythmias, cardiac Domperidone Long QT Review Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults without cancer. Material and Methods: Systematic searches in MEDLINE, LILACS, SciELO, the Cochrane Library and regulatory agencies websites were performed, followed by a manual search of cited references. The search strategy consisted of combining free and indexed text words without any date or language restriction. Results: Three case-control studies met the inclusion criteria; none of them evaluated QT interval prolongation. With low risk of bias, each study quantified the risk of ventricular arrhythmia or sudden cardiac death (VA/SCD). The odds ratios for these events in these studies were 4.7 (95% confidence interval (CI): 1.4-16), 1.59 (95% CI: 1.28-1.98) and 11.02 (95% CI: 2.02-62.3) respectively. A significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Conclusions: Heterogeneity between selected studies did not allow the computation of a summary measure. However, evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.1 20152015-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002es10.4067/S0034-98872015000100002 |
institution |
Scielo Chile |
collection |
Scielo Chile |
language |
Spanish / Castilian |
topic |
Arrhythmias, cardiac Domperidone Long QT Review |
spellingShingle |
Arrhythmias, cardiac Domperidone Long QT Review Marzi,Marta Weitz,Darío Avila,Aylén Molina,Gabriel Caraballo,Lucía Piskulic,Laura Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
description |
Background: Domperidone is widely prescribed in patients with gastrointestinal disorders but some cardiac adverse effects have been recently reported. Aim: To evaluate the risk of QT prolongation, ventricular arrhythmias and sudden cardiac death associated with the use of oral domperidone in adults without cancer. Material and Methods: Systematic searches in MEDLINE, LILACS, SciELO, the Cochrane Library and regulatory agencies websites were performed, followed by a manual search of cited references. The search strategy consisted of combining free and indexed text words without any date or language restriction. Results: Three case-control studies met the inclusion criteria; none of them evaluated QT interval prolongation. With low risk of bias, each study quantified the risk of ventricular arrhythmia or sudden cardiac death (VA/SCD). The odds ratios for these events in these studies were 4.7 (95% confidence interval (CI): 1.4-16), 1.59 (95% CI: 1.28-1.98) and 11.02 (95% CI: 2.02-62.3) respectively. A significantly increased risk was observed in patients older than 60 years of age or receiving doses > 30 mg/day. Conclusions: Heterogeneity between selected studies did not allow the computation of a summary measure. However, evidence was found that an increased risk of VA/SCD is associated with the use of oral domperidone in adults. |
author |
Marzi,Marta Weitz,Darío Avila,Aylén Molina,Gabriel Caraballo,Lucía Piskulic,Laura |
author_facet |
Marzi,Marta Weitz,Darío Avila,Aylén Molina,Gabriel Caraballo,Lucía Piskulic,Laura |
author_sort |
Marzi,Marta |
title |
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
title_short |
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
title_full |
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
title_fullStr |
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
title_full_unstemmed |
Efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
title_sort |
efectos adversos cardíacos de la domperidona en pacientes adultos: revisión sistemática |
publisher |
Sociedad Médica de Santiago |
publishDate |
2015 |
url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000100002 |
work_keys_str_mv |
AT marzimarta efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica AT weitzdario efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica AT avilaaylen efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica AT molinagabriel efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica AT caraballolucia efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica AT piskuliclaura efectosadversoscardiacosdeladomperidonaenpacientesadultosrevisionsistematica |
_version_ |
1718436797310042112 |